- Published on
Emergency and Acute Medicine – Atrial Fibrillation
Clinical Overview
Atrial fibrillation is a dysrhythmia marked by chaotic atrial electrical activity without effective atrial contraction, caused by multiple reentrant wavelets within the atria. Atrial rates typically range from 350 to 600 beats per minute, resulting in loss of coordinated atrial systole, an irregularly irregular ventricular response, reduced cardiac output, and a significant risk of thromboembolism. It is the most common sustained clinical arrhythmia, with prevalence increasing with age and a higher incidence in men.
Etiology And Risk Factors
Atrial fibrillation commonly arises in the setting of systemic illness, including hypertension, hyperthyroidism, chronic lung disease, infection, pulmonary embolism, hypoxia, electrolyte abnormalities, obesity, thyroid disease, sympathomimetic drug use, and acute alcohol ingestion known as holiday heart syndrome. Cardiac causes include cardiomyopathy, coronary artery disease, valvular disease—particularly mitral pathology—pericarditis, sick sinus syndrome, myocardial contusion, congestive heart failure, and congenital heart disease. In some patients, atrial fibrillation is idiopathic, with no identifiable systemic or structural heart disease on clinical or echocardiographic evaluation.
Clinical Manifestations
Patients may present with palpitations or symptoms related to decreased cardiac output such as weakness, lightheadedness, syncope, hypotension, angina, pulmonary edema, altered mental status, peripheral edema, or a positive hepatojugular reflex. Thromboembolic complications may manifest as acute neurologic deficits or mesenteric ischemia. History should focus on symptom onset, duration, triggering factors, prior episodes, and known cardiac disease. Physical examination classically reveals an irregularly irregular pulse, absence of A waves in the jugular venous pulse, and a pulse deficit in which the apical rate exceeds the peripheral pulse rate at higher ventricular rates.
Initial Evaluation
Assessment begins with history and physical examination to determine hemodynamic stability and the need for immediate cardioversion, as well as estimating symptom duration relative to the 48-hour threshold. Electrocardiography is essential and demonstrates absent P waves replaced by fibrillatory waves with variable morphology and amplitude, an irregularly irregular R–R interval, absence of an isoelectric baseline, and a ventricular rate typically between 80 and 150 beats per minute. Rates exceeding 200 beats per minute with a wide and irregular QRS complex raise concern for an accessory pathway. QRS complexes are usually narrow unless functional aberrancy, preexisting bundle branch block, or preexcitation is present.
Diagnostic Studies
Laboratory testing includes a complete blood count, serum electrolytes, thyroid function tests, cardiac biomarkers when ischemia is suspected, digoxin level if applicable, anticoagulation parameters, and urine toxicology screening when indicated. Chest radiography may assist in evaluating heart failure or pulmonary pathology. Continuous ECG monitoring is required.
Differential Diagnosis
Important considerations include atrial flutter with variable atrioventricular block, multifocal atrial tachycardia, sinus rhythm with frequent premature atrial contractions, and atrial tachycardia with variable conduction.
Prehospital And Immediate Management
Initial care includes intravenous access, oxygen, cardiac monitoring, and prompt synchronized cardioversion in unstable patients. In the emergency department, unstable or life-threatening presentations such as myocardial infarction, pulmonary edema, or refractory heart failure require immediate synchronized electrical cardioversion. Biphasic cardioversion is preferred, starting at 100 joules, while monophasic shocks typically begin at 200 joules.
Rhythm And Rate Control Strategies
For symptom duration under 48 hours, cardioversion may be pursued with consideration of intravenous heparin beforehand. If symptoms exceed 48 hours, anticoagulation is required, transesophageal echocardiography should be performed to exclude atrial thrombus prior to cardioversion, and anticoagulation must continue for four weeks afterward unless emergent cardioversion is required for instability. Chemical cardioversion options include ibutilide, procainamide, flecainide, propafenone, and sotalol, selected based on comorbid conditions such as heart failure, left ventricular hypertrophy, or coronary disease, with careful monitoring for proarrhythmia.
In hemodynamically stable patients, rate control is often preferred when symptom duration exceeds 48 hours, as rhythm control offers no mortality advantage. Rate control is unnecessary if the ventricular rate is below 100 beats per minute or spontaneous conversion occurs. Calcium channel blockers, beta-blockers, or digoxin may be used, except in suspected accessory pathway syndromes such as Wolff–Parkinson–White, where atrioventricular nodal blockers are contraindicated. Procainamide or ibutilide, or electrical cardioversion, are preferred in these cases. Amiodarone may be considered for refractory atrial fibrillation and is the only agent with strong evidence supporting outpatient initiation.
Anticoagulation Considerations
Stroke risk is stratified using the CHADS₂ score, assigning one point each for heart failure, hypertension, age 75 years or older, and diabetes, and two points for prior stroke or transient ischemic attack. A score of zero supports aspirin therapy alone, a score of one allows either aspirin or adjusted-dose warfarin, and scores greater than one require warfarin with a target INR of 2 to 3. Annual stroke risk rises sharply with increasing score. Aspirin is reserved for low-risk patients or those with contraindications to anticoagulation.
Pharmacologic Therapy
Medications used include beta-blockers such as metoprolol, calcium channel blockers such as diltiazem or verapamil, digoxin, amiodarone, procainamide, ibutilide, flecainide, propafenone, sotalol, and anticoagulants including unfractionated heparin, low-molecular-weight heparin, warfarin, and aspirin. Several intravenous antiarrhythmics are not approved for use in the United States and must be administered cautiously with close monitoring.
Disposition And Follow-Up
Admission is indicated for unstable atrial fibrillation, inability to achieve rate control, high stroke risk, associated heart failure, or contributing medical conditions requiring inpatient care. Discharge may be appropriate for patients who convert to sinus rhythm with symptoms under 48 hours, those with chronic atrial fibrillation who achieve adequate rate control and anticoagulation, or new-onset atrial fibrillation with stable control and treatment initiation. Cardiology referral is recommended for outpatient cardioversion or electrophysiologic evaluation. Patients on warfarin require close INR monitoring and should return immediately for symptoms such as syncope, focal neurologic deficits, or visual or speech disturbances.
Key Clinical Insights And Safety Considerations
Synchronized cardioversion is mandatory in hemodynamically unstable atrial fibrillation. Rate and rhythm control should be individualized in stable patients. Misinterpretation of fibrillatory or U waves as P waves can lead to missed diagnosis. Atrioventricular nodal blocking agents must be avoided in atrial fibrillation with wide-complex tachycardia due to an accessory pathway, as they may precipitate ventricular fibrillation.
Clinical Overview
Atrial fibrillation is a dysrhythmia marked by chaotic atrial electrical activity without effective atrial contraction, caused by multiple reentrant wavelets within the atria. Atrial rates typically range from 350 to 600 beats per minute, resulting in loss of coordinated atrial systole, an irregularly irregular ventricular response, reduced cardiac output, and a significant risk of thromboembolism. It is the most common sustained clinical arrhythmia, with prevalence increasing with age and a higher incidence in men.
Etiology And Risk Factors
Atrial fibrillation commonly arises in the setting of systemic illness, including hypertension, hyperthyroidism, chronic lung disease, infection, pulmonary embolism, hypoxia, electrolyte abnormalities, obesity, thyroid disease, sympathomimetic drug use, and acute alcohol ingestion known as holiday heart syndrome. Cardiac causes include cardiomyopathy, coronary artery disease, valvular disease—particularly mitral pathology—pericarditis, sick sinus syndrome, myocardial contusion, congestive heart failure, and congenital heart disease. In some patients, atrial fibrillation is idiopathic, with no identifiable systemic or structural heart disease on clinical or echocardiographic evaluation.
Clinical Manifestations
Patients may present with palpitations or symptoms related to decreased cardiac output such as weakness, lightheadedness, syncope, hypotension, angina, pulmonary edema, altered mental status, peripheral edema, or a positive hepatojugular reflex. Thromboembolic complications may manifest as acute neurologic deficits or mesenteric ischemia. History should focus on symptom onset, duration, triggering factors, prior episodes, and known cardiac disease. Physical examination classically reveals an irregularly irregular pulse, absence of A waves in the jugular venous pulse, and a pulse deficit in which the apical rate exceeds the peripheral pulse rate at higher ventricular rates.
Initial Evaluation
Assessment begins with history and physical examination to determine hemodynamic stability and the need for immediate cardioversion, as well as estimating symptom duration relative to the 48-hour threshold. Electrocardiography is essential and demonstrates absent P waves replaced by fibrillatory waves with variable morphology and amplitude, an irregularly irregular R–R interval, absence of an isoelectric baseline, and a ventricular rate typically between 80 and 150 beats per minute. Rates exceeding 200 beats per minute with a wide and irregular QRS complex raise concern for an accessory pathway. QRS complexes are usually narrow unless functional aberrancy, preexisting bundle branch block, or preexcitation is present.
Diagnostic Studies
Laboratory testing includes a complete blood count, serum electrolytes, thyroid function tests, cardiac biomarkers when ischemia is suspected, digoxin level if applicable, anticoagulation parameters, and urine toxicology screening when indicated. Chest radiography may assist in evaluating heart failure or pulmonary pathology. Continuous ECG monitoring is required.
Differential Diagnosis
Important considerations include atrial flutter with variable atrioventricular block, multifocal atrial tachycardia, sinus rhythm with frequent premature atrial contractions, and atrial tachycardia with variable conduction.
Prehospital And Immediate Management
Initial care includes intravenous access, oxygen, cardiac monitoring, and prompt synchronized cardioversion in unstable patients. In the emergency department, unstable or life-threatening presentations such as myocardial infarction, pulmonary edema, or refractory heart failure require immediate synchronized electrical cardioversion. Biphasic cardioversion is preferred, starting at 100 joules, while monophasic shocks typically begin at 200 joules.
Rhythm And Rate Control Strategies
For symptom duration under 48 hours, cardioversion may be pursued with consideration of intravenous heparin beforehand. If symptoms exceed 48 hours, anticoagulation is required, transesophageal echocardiography should be performed to exclude atrial thrombus prior to cardioversion, and anticoagulation must continue for four weeks afterward unless emergent cardioversion is required for instability. Chemical cardioversion options include ibutilide, procainamide, flecainide, propafenone, and sotalol, selected based on comorbid conditions such as heart failure, left ventricular hypertrophy, or coronary disease, with careful monitoring for proarrhythmia.
In hemodynamically stable patients, rate control is often preferred when symptom duration exceeds 48 hours, as rhythm control offers no mortality advantage. Rate control is unnecessary if the ventricular rate is below 100 beats per minute or spontaneous conversion occurs. Calcium channel blockers, beta-blockers, or digoxin may be used, except in suspected accessory pathway syndromes such as Wolff–Parkinson–White, where atrioventricular nodal blockers are contraindicated. Procainamide or ibutilide, or electrical cardioversion, are preferred in these cases. Amiodarone may be considered for refractory atrial fibrillation and is the only agent with strong evidence supporting outpatient initiation.
Anticoagulation Considerations
Stroke risk is stratified using the CHADS₂ score, assigning one point each for heart failure, hypertension, age 75 years or older, and diabetes, and two points for prior stroke or transient ischemic attack. A score of zero supports aspirin therapy alone, a score of one allows either aspirin or adjusted-dose warfarin, and scores greater than one require warfarin with a target INR of 2 to 3. Annual stroke risk rises sharply with increasing score. Aspirin is reserved for low-risk patients or those with contraindications to anticoagulation.
Pharmacologic Therapy
Medications used include beta-blockers such as metoprolol, calcium channel blockers such as diltiazem or verapamil, digoxin, amiodarone, procainamide, ibutilide, flecainide, propafenone, sotalol, and anticoagulants including unfractionated heparin, low-molecular-weight heparin, warfarin, and aspirin. Several intravenous antiarrhythmics are not approved for use in the United States and must be administered cautiously with close monitoring.
Disposition And Follow-Up
Admission is indicated for unstable atrial fibrillation, inability to achieve rate control, high stroke risk, associated heart failure, or contributing medical conditions requiring inpatient care. Discharge may be appropriate for patients who convert to sinus rhythm with symptoms under 48 hours, those with chronic atrial fibrillation who achieve adequate rate control and anticoagulation, or new-onset atrial fibrillation with stable control and treatment initiation. Cardiology referral is recommended for outpatient cardioversion or electrophysiologic evaluation. Patients on warfarin require close INR monitoring and should return immediately for symptoms such as syncope, focal neurologic deficits, or visual or speech disturbances.
Key Clinical Insights And Safety Considerations
Synchronized cardioversion is mandatory in hemodynamically unstable atrial fibrillation. Rate and rhythm control should be individualized in stable patients. Misinterpretation of fibrillatory or U waves as P waves can lead to missed diagnosis. Atrioventricular nodal blocking agents must be avoided in atrial fibrillation with wide-complex tachycardia due to an accessory pathway, as they may precipitate ventricular fibrillation.
0 Comments
